Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States

BACKGROUND: The anti-programmed death receptor-1 (anti–PD-1) pembrolizumab is approved as first-line monotherapy for metastatic non-small cell lung cancer (mNSCLC) with PD-ligand 1 (PD-L1) tumor expression ≥50%. Most studies comparing PD-L1 results by immunohistochemistry (IHC) assay type have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Velcheti, Vamsidhar, Patwardhan, Pallavi D., Liu, Frank Xiaoqing, Chen, Xin, Cao, Xiting, Burke, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224125/
https://www.ncbi.nlm.nih.gov/pubmed/30408065
http://dx.doi.org/10.1371/journal.pone.0206370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224125/
https://www.ncbi.nlm.nih.gov/pubmed/30408065
http://dx.doi.org/10.1371/journal.pone.0206370

Ejemplares similares